Clinician's Roundtable

For patients at average risk of colorectal cancer (CRC), the United States Preventative Services Task Force recommends screening with either the multi-target stool DNA test or fecal immunochemical test. But in light of new performance data that compared a multi-target stool DNA test and a fecal immunochemical test, a poster presented at the 2024 Digestive Disease Week conference re-evaluated the benefits and harms associated with each test. Tune in to learn more about the findings and their implications for CRC screening.

The United States Preventative Services Task Force endorses multiple screening options for patients at average-risk of colorectal cancer (CRC). These options include colonoscopy, multi-target stool DNA, and the fecal immunochemical test. However, performance data for non-endorsed options like multi-target stool RNA and blood-based screening tests have recently been published. That’s why a recent poster presented at the 2024 Digestive Disease Week conference compared the benefit-to-harm ratio for guideline-endorsed versus non-endorsed CRC screening tests. Tune in to learn more about the findings and their implications for CRC screening.

Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Disease Week (DDW) 2024 to help eliminate the colonoscopy backlog with stool-based CRC screening options. To learn the details of this study and how we can incorporate the findings into practice, join Dr. Jennifer Caudle as she speaks with Dr. Mark Fendrick, Professor of Internal Medicine in the School of Medicine and Professor of Health Management and Policy in the School of Public Health at the University of Michigan.

There is a high unmet need for patients with persistent chylomicronemia. Plozasiran (ARO-APOC3) is an investigational drug that is being evaluated for these patients. Professor Gerald Watts shares the outcomes of the PALISADE trial, in which the efficacy and safety of plozasiran was examined in patients with familial chylomicronemia syndrome.

A recent study that looked at psoriasis in patients from different races and backgrounds found that there weren’t a significant number of differences in the factors studied between patients with skin of color and Caucasian patients. The one thing that was really quite impactful for patients who are Black is that they wanted to see more physicians who could speak to their cultural and ethnic backgrounds. So to learn more about the findings and how we can address these barriers, join Dr. Charles Turck as he dives in with Dr. Amy McMichael, Professor in the Department of Dermatology at Wake Forest School of Medicine in Winston-Salem, North Carolina.

Patients with psoriasis die about five years younger than those without the condition, and cardiovascular disease is the leading cause of this premature mortality. Tune in to hear Dr. John Barbieri discuss strategies to identify risk factors and improve cardiovascular disease prevention in patients with psoriasis. Dr. Barbieri is an Assistant Professor of Dermatology at Brigham and Women's Hospital at Harvard Medical School in Boston.

Several different professional organizations have created guidelines for screening for alpha-1 antitrypsin deficiency (AATD) in COPD that can help us proactively detect and treat patients. Joining Dr. Charles Turck to break down those various guideline recommendations and share best practices for implementing them into clinical practice is Dr. David Mares, who specializes in adult pulmonology and critical care in Anderson, Indiana.

Click here to order free AlphaID™ screening kits to rule out Alpha-1 deficiency in your patients.

It’s absolutely critical to proactively detect alpha-1 antitrypsin deficiency (AATD) in our patients with COPD, but it’s just as important to know how to manage patients with this deficiency once we reach a diagnosis. That’s why Dr. David Mares joins Dr. Charles Turck to share his experiences and a patient case in managing AATD-associated COPD. Dr. David Mares is an adult pulmonology and critical care specialist at Ascension St. Vincent Anderson Hospital in Indiana.

Click here to order free AlphaID™ screening kits to rule out Alpha-1 deficiency in your patients.

According to the current recommendations, we should be testing all patients with COPD for alpha-1 antitrypsin deficiency (AATD). But unfortunately, there are many barriers that can keep us from following these recommendations. That’s why Dr. Brian Smith joins Dr. Charles Turck to share strategies for addressing those barriers and proactively detecting AATD in patients with COPD. Dr. Smith specializes in Family Medicine and Hospice and Palliative Medicine at Versailles Family Medicine in Kentucky.

Click here to order free AlphaID™ screening kits to rule out Alpha-1 deficiency in your patients.

Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.